TuHURA Biosciences Inc. (HURA)
NASDAQ: HURA
· Real-Time Price · USD
2.37
0.02 (0.85%)
At close: Sep 10, 2025, 3:59 PM
2.42
2.11%
After-hours: Sep 10, 2025, 07:27 PM EDT
Company Description
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy.
The company is headquartered in Tampa, FL.
TuHURA Biosciences Inc.
| Country | United States |
| IPO Date | Feb 22, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | James A. Bianco |
Contact Details
Address: 10500 University Center Drive Tampa, United States | |
| Website | http://www.tuhurabio.com |
Stock Details
| Ticker Symbol | HURA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001498382 |
| CUSIP Number | n/a |
| ISIN Number | US8989201038 |
| Employer ID | 99-0360497 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James A. Bianco M.D. | President, Chief Executive Officer & Director |
| Dan Dearborn CPA | Executive Vice President of Finance & Chief Financial Officer |
| Dr. Bertrand Le Bourdonnec Ph.D. | Executive Vice President, Head of Drug Discovery, Early Development, & Program Management |
| Michael Krsulich | Head of Quality Assurance |
| Michael Lawman | Co-Founder |
| Patricia Lawman | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Aug 14, 2025 | 8-K | Current Report |
| Aug 12, 2025 | S-1 | Filing |
| Aug 12, 2025 | 8-K/A | [Amend] Current Report |
| Jul 29, 2025 | SCHEDULE 13G | Filing |
| Jun 30, 2025 | 8-K | Current Report |
| Jun 27, 2025 | 8-K | Current Report |
| Jun 24, 2025 | 425 | Filing |